Company: NCEL
Filing Date: 2025-01-16
Form Type: 425
Source: 0001213900-25-004028
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-01-16
Form: 425
Chunk 1
---
 January 16, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:-----------------------|:-----------------------|:--------------------|:------------------------|
|                        |                        | Name:               | Alexander Zwyer         |
|                        |                        | Title:              | Chief Executive Officer |

<div align='center'>2</div>

Exhibit 99.1

<div align='center'>Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

Kadimastem Approaches Final Steps for Securing Merger Completion</div>

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL—
January 16 2025 — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical
company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem
Ltd. (“Kadimastem”) (TASE: KDST.TA), a clinical-stage cell therapy company developing and manufacturing “off-the-shelf”
allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announces that Kadimastem has
issued a notice to convene a special general meeting of Kadimastem’s shareholders to approve the merger transaction with NLS. The
Central District Court in Israel has approved that this meeting may occur within a reduced time frame of only 14 days from the date of
publication of the meeting notice. This meeting is needed to secure Kadimastem’s shareholder approval which are critical to completing
the merger process.

This pivotal step follows NLS’s recent announcements regarding
the successful initial closing of $500,000 from a previously announced $1 million fundraising round, executed at a share price of $3.10—representing
a significant 48% increase above the market price at the time of the pricing of the transaction. This financing, along with a previously
disclosed $3.2 million investment in October 2024, lays the groundwork for facilitating the proposed merger with NLS , which aims to create
a combined Nasdaq-traded biotechnology company with a robust pipeline of advanced therapies.

Additionally, NLS has recently filed F-4 Registration Statement on
Form F-4 with the U.S. Securities and Exchange Commission (